Postal Strike Update | Mise à jour sur la grève du Syndicat des travailleurs et travailleuses des postes

Show more Show less

Government of Saskatchewan ministries, Crown corporations and organizations are implementing contingency plans to minimize the impacts of postal service disruption.

Les ministères, sociétés d’État et organismes du gouvernement de la Saskatchewan mettent en œuvre des plans d’urgence visant à réduire les répercussions de l’interruption du service des postes.

Language

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Saskatchewan to Cover New MS Drug

Released on April 30, 2014

Saskatchewan multiple sclerosis (MS) patients will soon have access to a new oral medication.  Beginning May 1, 2014, the province will provide coverage of Tecfidera (dimethyl fumarate) to treat adult MS patients with relapsing-remitting MS who meet certain criteria.

“MS patients and specialists have been asking for coverage of this medication and our government is pleased to make it more accessible to those who need it,” Health Minister Dustin Duncan said.  “This option does not require injections, and has the potential to improve the quality of life for MS patients by reducing the number of relapses they experience and slowing the progression of the disease.”

MS is a neurological disease that impairs or destroys the function of nerve cells in the brain and spinal cord.  About 3,700 Saskatchewan people are affected – a higher per capita rate than anywhere else in Canada.

“The MS Society is very pleased with the news that Saskatchewan has given people living with MS in our province access to another option to manage the effects of their disease,” MS Society’s Saskatchewan Division Communication Manager Virginia Harper said.  “With many new MS drugs coming on the market and offering a variety of ways they can be administered, we are happy the Ministry of Health continues to be responsive in the public listing of these new therapies.  As always, we encourage all people living with MS to consult with their physician to find the course of treatment most appropriate for them.”

Saskatchewan is the first province among pan-Canadian Pricing Alliance (PCPA) members to provide coverage.  Quebec, which is not part of the PCPA, also covers the drug.  Saskatchewan led the negotiations which recently resulted in a pricing agreement between the drug manufacturer and provinces and territories.  The PCPA capitalizes on the combined negotiating power of provinces and territories to obtain the best value for Canadians.  Tecfidera was approved by Health Canada for use by MS patients in 2013.

MS patients seeking more information are encouraged to talk with their physicians, or call the Saskatchewan MS Drugs Program at 306-655-8400.  The amount a patient would pay per prescription will be determined by their level of coverage under the Saskatchewan Drug Plan.  Information on the Drug Plan’s Special Support Program is available online at www.health.gov.sk.ca/special-support or at 1-800-667-7581 (toll free) or 1-306-787-3317 (Regina).

-30-

For more information, contact:

Tyler McMurchy
Health
Regina
Phone: 306-787-4083
Email: tmcmurchy@health.gov.sk.ca
Cell: 306-537-3594

We need your feedback to improve saskatchewan.ca. Help us improve